OBJECTIVE: Disseminated gynecologic cancers are usually fatal due to chemoresistance. Recently, rationally developed, targeted agents are entering the early clinical trials setting. We assessed patients with metastatic gynecologic cancers in a dedicated phase I clinical trials clinic in order to determine their outcome. METHODS: We reviewed records for 89 consecutive patients with gynecologic cancers referred to the Phase I Clinical Trials Program, 85 (96%) of whom were treated on > or = 1 trial. RESULTS: Cancer diagnoses were ovarian (N=43), uterine (N=19), cervix (N=17), and other. Median age was 58 years; median number of prior cytotoxic regimens, five. Two patients (2.4%) achieved a CR; four (4.7%), a PR; and eight (9.4%), SD > or = 6 months (total CR/PR/SD > or = 6 months=16.5%) for the first phase I trial. Twenty-five patients enrolled on a second trial and three, on a third (N=113 trials total). Combining response data for all trials, of the 85 patients, two achieved CR (2.4%), nine achieved PR (10.6%), and 12 (14%) had SD for > or = 6 months. One-year survival was 30% (95% CI, 21% to 44%). There was no difference in time-to-treatment failure (TTF) on phase I versus the patient's last standard treatment. CONCLUSION: Twenty-three of 85 patients (27%) with advanced, heavily pretreated, gynecologic cancers achieved CR/PR/SD > or = 6 months on a phase I trial, and overall TTF on phase I was comparable to that of last conventional therapy, suggesting that participation in a phase I trial is a reasonable option for these patients. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: Disseminated gynecologic cancers are usually fatal due to chemoresistance. Recently, rationally developed, targeted agents are entering the early clinical trials setting. We assessed patients with metastatic gynecologic cancers in a dedicated phase I clinical trials clinic in order to determine their outcome. METHODS: We reviewed records for 89 consecutive patients with gynecologic cancers referred to the Phase I Clinical Trials Program, 85 (96%) of whom were treated on > or = 1 trial. RESULTS:Cancer diagnoses were ovarian (N=43), uterine (N=19), cervix (N=17), and other. Median age was 58 years; median number of prior cytotoxic regimens, five. Two patients (2.4%) achieved a CR; four (4.7%), a PR; and eight (9.4%), SD > or = 6 months (total CR/PR/SD > or = 6 months=16.5%) for the first phase I trial. Twenty-five patients enrolled on a second trial and three, on a third (N=113 trials total). Combining response data for all trials, of the 85 patients, two achieved CR (2.4%), nine achieved PR (10.6%), and 12 (14%) had SD for > or = 6 months. One-year survival was 30% (95% CI, 21% to 44%). There was no difference in time-to-treatment failure (TTF) on phase I versus the patient's last standard treatment. CONCLUSION: Twenty-three of 85 patients (27%) with advanced, heavily pretreated, gynecologic cancers achieved CR/PR/SD > or = 6 months on a phase I trial, and overall TTF on phase I was comparable to that of last conventional therapy, suggesting that participation in a phase I trial is a reasonable option for these patients. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Elizabeth Horstmann; Mary S McCabe; Louise Grochow; Seiichiro Yamamoto; Larry Rubinstein; Troy Budd; Dale Shoemaker; Ezekiel J Emanuel; Christine Grady Journal: N Engl J Med Date: 2005-03-03 Impact factor: 91.245
Authors: Linda S Steelman; Kristin M Stadelman; William H Chappell; Stefan Horn; Jörg Bäsecke; Melchiorre Cervello; Ferdinando Nicoletti; Massimo Libra; Franca Stivala; Alberto M Martelli; James A McCubrey Journal: Expert Opin Ther Targets Date: 2008-09 Impact factor: 6.902
Authors: J Warwick; E Vardaki; N Fattizzi; I McNeish; A Jeyarajah; D Oram; L Hassan; A Covens; S Duffy; K Reynolds Journal: BJOG Date: 2009-05-28 Impact factor: 6.531
Authors: Filip Janku; Jennifer J Wheler; Shannon N Westin; Stacy L Moulder; Aung Naing; Apostolia M Tsimberidou; Siqing Fu; Gerald S Falchook; David S Hong; Ignacio Garrido-Laguna; Rajyalakshmi Luthra; J Jack Lee; Karen H Lu; Razelle Kurzrock Journal: J Clin Oncol Date: 2012-01-23 Impact factor: 44.544
Authors: Daniele Xavier Assad; Silvia Taveira Elias; Andréia Cristina Melo; Carlos Gil Ferreira; Graziela De Luca Canto; Eliete Neves Silva Guerra Journal: Oncol Lett Date: 2016-09-20 Impact factor: 2.967
Authors: Lorna Rodriguez-Rodriguez; Kim M Hirshfield; Veronica Rojas; Robert S DiPaola; Darlene Gibbon; Mira Hellmann; Sara Isani; Aliza Leiser; Gregory M Riedlinger; Allison Wagreich; Siraj M Ali; Julia A Elvin; Vincent A Miller; Shridar Ganesan Journal: Gynecol Oncol Date: 2016-04 Impact factor: 5.482
Authors: John W Moroney; Matthew P Schlumbrecht; Thorunn Helgason; Robert L Coleman; Stacy Moulder; Aung Naing; Diane C Bodurka; Filip Janku; David S Hong; Razelle Kurzrock Journal: Clin Cancer Res Date: 2011-09-02 Impact factor: 12.531
Authors: Diane A J van der Biessen; Merlijn A Cranendonk; Gaia Schiavon; Bronno van der Holt; Erik A C Wiemer; Ferry A L M Eskens; Jaap Verweij; Maja J A de Jonge; Ron H J Mathijssen Journal: Oncologist Date: 2013-02-21
Authors: M Sureda; J Rebollo; E Mª Martínez-Navarro; F J Fernández-Morejón; J Farré; V Muñoz; P Bretcha-Boix; M Duarte; R G Manzano; A Crespo; M Del Carmen Redal; B Valenzuela; A Brugarolas Journal: Clin Transl Oncol Date: 2017-11-20 Impact factor: 3.405
Authors: Jennifer Wheler; Gerald Falchook; Apostolia M Tsimberidou; David Hong; Aung Naing; Sarina Piha-Paul; Su S Chen; John Heymach; Siqing Fu; Bettzy Stephen; Jansina Y Fok; Filip Janku; Razelle Kurzrock Journal: Oncotarget Date: 2013-05
Authors: Christopher H Bailey; Gayle Jameson; Chao Sima; Sharon Fleck; Erica White; Daniel D Von Hoff; Glen J Weiss Journal: J Cancer Date: 2011-11-28 Impact factor: 4.207